Healthcare technology developer Mindray North America has selected Aegle Medical Solutions as the exclusive distributor of its Hepatus-Series transient elastography diagnostic ultrasound systems in the US.
Aegle Medical Solutions’ expertise in integrating new technologies into clinical practices complements Mindray’s Hepatus-Series solution, designed to address the rising incidence of chronic liver disease.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The collaboration between Mindray and Aegle Medical Solutions reflects a shared dedication to improving patient outcomes in liver disease management.
Mindray North America president Wayne Quinn said: “As liver disease continues to grow as an epidemic, it is important for us to continuously find new ways to better serve patients by enabling their clinicians to get a clear view of liver health with innovative technologies and quantitative tools that are reliable.
“The partnership with Aegle to distribute the Hepatus-Series Ultrasound Systems provides us with an excellent opportunity to better serve those patients and expand our liver care offerings in the US market.”
Aegle Medical president and CEO Michael McTighe said: “We are extremely excited about this exclusive distribution agreement with Mindray to introduce to the US market their NexGen transient technology, called the Hepatus.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“At Aegle Medical, we are dedicated to supporting healthcare professionals with emerging technologies that improve their clinical confidence, diagnostic accuracy, and overall patient satisfaction, and that is exactly what Mindray has developed and delivered to the market with the introduction of the Hepatus platform.”
The Hepatus-Series ultrasound systems offer a non-invasive alternative for detecting and monitoring liver conditions, potentially reducing the discomfort and risks associated with traditional diagnostic methods such as liver biopsies.
Leveraging transient elastography, Hepatus-Series provides healthcare professionals with a comprehensive toolset for assessing liver fibrosis and steatosis.
This suite of quantitative tools is aimed at simplifying the diagnostic process while ensuring accuracy and reliability for clinicians.
Last July, Mindray Medical Netherlands agreed to acquire a 75% equity interest in DiaSys Diagnostic Systems from Gorka Holding for a preliminary purchase price of €115m.
